Con esta herramienta te facilitamos un acceso a todas las ofertas y demandas de tecnología europeas y a búsquedas de socios para participar en propuestas europeas de I+D publicadas en la red Enterprise Europe Network, pudiendo filtrar los resultados para facilitar las búsquedas más acordes con tus necesidades.
¿Quieres recibir estos listados de oportunidades de colaboración en tu correo de forma periódica y personalizada? Date de alta en nuestro Boletín
Los términos de búsqueda han de ser en inglés.
Frailty diagnosis through biomarkers
Resumen
Tipo:
Oferta Tecnológica
Referencia:
TOES20210204003
Publicado:
12/02/2021
Caducidad:
13/02/2022
Resumen:
A Spanish (Basque) scientific foundation specialized in R-Y-D and innovation management for the healthcare system seeks a company to license an in vitro (biomarker-based) method for diagnosing and/or predicting whether an individual is or is likely to become frail.
Details
Tittle:
Frailty diagnosis through biomarkers
Summary:
A Spanish (Basque) scientific foundation specialized in R-Y-D and innovation management for the healthcare system seeks a company to license an in vitro (biomarker-based) method for diagnosing and/or predicting whether an individual is or is likely to become frail.
Description:
Frailty is defined as a geriatric condition or syndrome characterised by a decline in functional reserve and adaptive capacity in older people. This decline leads to a general worsening in health that tends to progress towards dependency. Unlike dependency, frailty is reversible and there is substantial evidence of the effectiveness of interventions based on muscle strengthening through exercise, improving diet, and reducing polypharmacy, among other approaches. Frailty is independently associated with an elevated risk of death, loss of independence, falls and fractures, hospitalisations and reductions in health-related quality of life.
It is very important to identify frail older individuals as it makes it possible, through personalised interventions tailored to the needs of individuals and their families, to slow the natural progression of frailty towards dependency.
This invention provides a new method for the diagnosis of frail individuals and distinguishing them from more robust or dependent individuals based on measurements of the level of protein expression and/or transcription of a range of molecular markers identified by complete transcriptome analysis.
The organization is offering a license agreement to experienced companies from the health sector interested in acquiring this technology. Although it is not compulsory, it would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out.
It is very important to identify frail older individuals as it makes it possible, through personalised interventions tailored to the needs of individuals and their families, to slow the natural progression of frailty towards dependency.
This invention provides a new method for the diagnosis of frail individuals and distinguishing them from more robust or dependent individuals based on measurements of the level of protein expression and/or transcription of a range of molecular markers identified by complete transcriptome analysis.
The organization is offering a license agreement to experienced companies from the health sector interested in acquiring this technology. Although it is not compulsory, it would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out.
Advantages and Innovations:
The innovative diagnosis method is simple, rapid and reliable. It is important to note that it is a non-invasive method. Thus, no break in the skin is created and there is no contact with the mucosa, or skin break, or internal body cavity beyond a natural or artificial body orifice. Moreover, this method not only allows an early diagnosis but it also predicts the development of it.
This way, measures may be implemented to slow the illness progression towards a dependency state.
This way, measures may be implemented to slow the illness progression towards a dependency state.
Stage of Development:
Under development/lab tested
IPs:
Patent(s) applied for but not yet granted
CommeR Statunts Regarding IPR Status:
Patent Application
PCT
Priority Date: 27/07/2018
PCT
Priority Date: 27/07/2018
Partner sought
Type and Role of Partner Sought:
The Spanish (Basque) organization is offering a license agreement to experienced companies in preclinical and clinical development of medical devices and diagnostic kits interested in acquiring this technology. Moreover, this license offer seeks both options: On the one side, companies willing to commercialise, but also companies interested in enhancing the invention.
It would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out. Nevertheless, this is not compulsory.
It would be preferable for the partner to be a healthcare facility so that the validation of the method can be carried out. Nevertheless, this is not compulsory.
Client
Type and Size of Client:
R&D Institution
Already Engaged in Trans-National Cooperation:
No
Languages Spoken:
English
Spanish
Spanish
Keywords
Technology Keywords:
06001003 Citología, cancerología, oncología
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001013 Tecnología médica / ingeniería biomédica
06001002 Investigaciones clínicas, ensayos
06001012 Investigaciones médicas
06001013 Tecnología médica / ingeniería biomédica
een_ader
